High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
- PMID: 29201413
- PMCID: PMC5683469
- DOI: 10.1186/s40834-016-0035-0
High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
Abstract
Background: Depot medroxyprogesterone acetate (DMPA) contraceptive use is associated with an increased risk for Chlamydia infection. However, prior studies inadequately account for potential differences in sexual behavior between users of DMPA and users of other contraceptive methods. In this study we compare sexual risk-taking behavior in women using DMPA to women using oral contraceptive pills (OCP) to assess risk of Chlamydia trachomatis infection.
Methods: In this cross-sectional study of 630 reproductive-aged women seeking routine gynecologic care (449 OCP and 181 DMPA users) sexual risk-taking was evaluated by use of the Safe Sex Behavior Questionnaire, a validated measure of sexual behaviors and attitudes. All women were screened for Chlamydia. Logistic regression estimated the association of contraceptive choice, sexual behaviors, and Chlamydia infection.
Results: Oral contraceptive pill users differed from DMPA users in age, race, marital status, education level, and pregnancy history (p-values all <0.05). Oral contraceptive pill users had used their method of contraception for longer average duration (p < 0.01) and reported greater frequency of condom use (p < 0.01). Eleven (2.5%) OCP and 2 (1.1%) DMPA users had Chlamydia (p = NS).
Conclusions: Oral contraceptive pill and DMPA users differed with respect to both demographic factors and frequency of condom use. Odds of current Chlamydia infection did not differ between OCP and DMPA users when controlling for sexual risk-taking or demographic factors, though due to low Chlamydia rates in our population, this study was underpowered to detect this difference.
Keywords: Chlamydia; Depot medroxyprogesterone acetate; Oral contraceptive pills; Sexual behavior.
Similar articles
-
The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.Clin Endocrinol (Oxf). 1998 Nov;49(5):615-8. doi: 10.1046/j.1365-2265.1998.00582.x. Clin Endocrinol (Oxf). 1998. PMID: 10197077
-
Bone density in women receiving depot medroxyprogesterone acetate for contraception.BMJ. 1991 Jul 6;303(6793):13-6. doi: 10.1136/bmj.303.6793.13. BMJ. 1991. PMID: 1830502 Free PMC article.
-
Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.Contraception. 2015 Dec;92(6):553-9. doi: 10.1016/j.contraception.2015.06.013. Epub 2015 Jun 17. Contraception. 2015. PMID: 26093190
-
Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.J Reprod Med. 1996 May;41(5 Suppl):419-27. J Reprod Med. 1996. PMID: 8725705 Review.
-
Depo Provera. Position paper on clinical use, effectiveness and side effects.Br J Fam Plann. 1999 Jul;25(2):69-76. Br J Fam Plann. 1999. PMID: 10454658 Review.
Cited by
-
Contraceptive use and the risk of sexually transmitted infection: systematic review and current perspectives.Open Access J Contracept. 2018 Nov 12;9:91-112. doi: 10.2147/OAJC.S135439. eCollection 2018. Open Access J Contracept. 2018. PMID: 30519127 Free PMC article. Review.
References
-
- United Nations Department of Economic and Social Affairs. World contraceptive use 2007. New York: United Nations; 2008.
-
- Johnson NB, Hayes LD, Brown K, et al. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013. MMWR Surveill Summ. 2014;63:3–27. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous